The theories and processes used by Blacklight Biotechnology in developing the genetic recombination vaccine were published first-hand by the weekly scientific journal, Nature. This had allowed many countries to acquire the vaccine's manufacturing technology in time.
Although the vaccine had only undergone a month's duration of clinical trials, it was tested on more than five thousand participants. This sample size was sufficient to demonstrate the safety of the vaccine.
However, the African Continent was a tricky situation. The Earth Federation could not depend on it to produce enough vaccines on their own even if they had spoon fed them the technology. The Earth Federation needed to hold a few rounds of conferences to distribute the tasks of producing the vaccines.